Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07600736

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy

Conditions: KCNT1-Related Epilepsy

Sex: All

Ages: 1 Month – 21 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 45

Sponsor: Actio Biosciences, Inc.

Location: Northeast Regional Epilepsy Group Hackensack New Jersey

Summary

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Eligibility Criteria

Inclusion Criteria: * Aged 1 month to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07600736). StuddyBuddy aggregates publicly available trial information.